STOCKS TELEGRAPH

Tag: ECOR

  • ElectroCore Inc. (ECOR) stock Succumbs to Corrections After Hours

    ElectroCore Inc. (ECOR) stock Succumbs to Corrections After Hours

    Following a huge gain of 64.03% in regular trading, ElectroCore Inc. (ECOR) fell under corrections in the after-hours on Wednesday. The stock gained big on the news of Breakthrough Device Designation.

    During the regular session, ECOR stock varied between a high of $0.9800 and a low of $0.5629. The news caused the stock to close the session at $0.8800 on Wednesday. Consequently, the stock lost 13.58% to corrections in the after hours. Hence, ECOR was trading at $0.7605 apiece in the after-hours at a volume of 2.9 million shares.

    The non-invasive vagus nerve stimulation (nVNS) therapy solutions provider, ElectroCore Inc. (ECOR) has a market capitalization of $37.93 million). Currently, the company’s outstanding shares in the market are 70.7 million.

    What Happened to ECOR?

    On January 12, ElectroCore Inc. announced receiving Breakthrough Device Designation for its gammaCoreTM nVNS device. The news caused investors to flock towards the stock, making it soar at a huge volume of 79.44 million. The day’s volume was a humungous 4,218% of its 65-day average of 1.88 million. Consequent to the announcement, ECOR made a big jump of over 64% in the regular session. Given the huge gain, the stock was bound to fall under corrections. Subsequently, the stock succumbed to corrections in the after-hours on Wednesday.

    Looking at the bigger picture, ECOR had added a good 57.42% in the past five days and 31.34% last month. Moreover, the year-to-date gain of the stock stands at 51.05% while it lost 47.62% last year.

    GammaCoreTM (nVNS) Device

    ECOR’s GammaCoreTM is the first non-invasive hand-held medical therapy that can be self-administered. The device causes the reduction of various kinds of pains in patients including migraine and cluster headache.

    Recently, in a sham-controlled study, gammaCore demonstrated 31% reductions in symptoms of PTSD. Based on this, the U.S. FDA granted Breakthrough Device Designation to the device for the treatment of post-traumatic stress disorder.

    Every year, almost 15 million adults suffer from PTSD in the U.S., according to the Department of Veterans Affairs National Center for PTSD. Currently, PTSD treatments involve medication and psychotherapy that come with limitations and side effects. Moreover, patients have been known to show unwillingness to psychotherapy treatments due to fear of reliving the traumatic memories. Hence, gammaCore brings a breakthrough solution that is cost-effective, non-invasive, safe, and has lower side effects.

    ECOR’s Financial Highlights

    In the third quarter of 2021, ECOR had a net loss of $4.0 million on net sales of $1.5 million. Comparatively, net loss was $4.5 million on net sales of $1.1 million in Q3 of 2020.

  • electroCore, Inc. (ECOR) Stock Surged in After Market. Here’s What you Should Know

    electroCore, Inc. (ECOR) is a leading innovative development and commercialization bioelectronic medicine company. The company primarily focuses on the treatment of different neurological conditions through its non-invasive vagus nerve stimulation therapy (nVNS). The company specializes in making therapies for patients with migraine, episodic cluster headaches, and hemicrania.

    The price of ECOR stock during the regular trading on December 23, 2021, was $0.69 with an incline of 3.81%. At last check in the aftermarket, the stock was further significantly up by 6.47%.

    ECOR: Event and Happenings

    On December 16, 2021, ECOR reported about its collaboration with different global and well-known distribution partners for giving the exclusive distribution rights of gammaCore Sapphiren nVNS in Cyprus and the Gulf States. On December 15, 2021, ECOR unveiled an e-commerce webshop for patients. People who wanted to purchase a gammaCore Sapphire nVNS device were required to fill a healthcare questionnaire.

    On December 14, 2021, ECOR reported about the clinical trials to evaluate the potential of gammaCore nVNS for the treatment of Post Traumatic Stress Disorder. The patients reported significant improvement in their overall condition. On December 13, 2021, ECOR reported that the United States Patent and Trademark Office had issued Patent No. 11,191,953 to ECOR. The number was issued in relation to the treatment of acute stroke symptoms or transient ischemic attack.

    On November 11, 2021, ECOR reported that the top officials of the company presented at the Virtual Canaccord Genuity MedTech & Diagnostics Forum on November 18, 2021.

    ECOR: Key Financials

    On November 04, 2021, ECOR reported third-quarter 2021 financial results that ended September 30, 2021. Some of the highlights are as follows

    Revenue

    Revenue of $1.5 million was reported for Q3 2021 representing an increase of 38% from the same period of 2020.

    Net Loss per Share

    Basic and diluted net loss per share for Q3 2021 was $3.9 million or $0.06 per share as compared to the same period of 2020 when it was $4.18 million or $0.10 per share.

    Total Assets

    The total assets of ECOR for Q3 2021 were reported to be $47.5 million.

    On October 20, 2021, ECOR reported the research published in the British Journal of Healthcare Management. The title of the paper was “nVNS for treatment of cluster headache: a retrospective review of prescribing in England,”. On October 14, 2021, ECOR reported that it received a revised Medical Device License from Canadian Health Department to expand the label of gammaCore nVNS in adolescents.

    On September 30, 2021, ECOR reported that the top management of the company presented at the Cantor Fitzgerald Virtual Global Healthcare Conference held on September 30, 2021.

    Conclusion

    Although ECOR stock declined 6% from the past month. But the recent surge in the stock price which is mainly the result of uncertain market conditions has proven beneficial for the company’s stockholders. Analysts are suggesting that the company has the potential to attract potential investments.

  • electroCore Inc. (ECOR) Stock on the Rise Following Announcement of Newly Issued Patent

    electroCore Inc. (ECOR) stock prices were up 3.92% as of the market closing on July 27th, 2021, bringing the price per share up to USD$0.9665 at the end of the trading day. Subsequent premarket fluctuations saw the stock rise by 5.54%, bringing it up to USD$1.02.

    ECOR Stock’s Patent

    July 27th, 2021 announced that the United States Patent and Trademark Office (USPTO) has granted ECOR stock U.S. Patent No. 11,065,444. The patent issued to the commercial-stage bioelectronic medicine company is in regard to the use of a mobile phone for the stimulation of the trigeminal nerve to treat disorders. The new patent is owned by the company and is the most recent U.S patent to be issued in connection with the company’s development of non-invasive solution programs for pain.

    Patented Technology

    The newly issued patent includes descriptions of devices and methods that can be used by patients themselves to treat medical conditions, such as migraine headaches, with non-invasive means. ECOR stock achieves this by the electrical stimulation of nerves in the head, particularly supraorbital, supratrochlear, infraorbital, and mental nerves in the general area of patients’ foramen or notch.

    About the Treatment

    The system consists of a handheld mobile device, like a smartphone, that is applied to the surface of the head of the patient being treated. Electrical impulses are applied through the patient’s skin via one or more electrodes, serving to modulate a targeted nerve to treat the medical condition. ECOR stock’s system aims to provide patients with a self-treatment solution in the absence of a medical professional.

    Expansive Scope of Treatment

    ECOR stock is keen to continue the advancement of its non-invasive treatment solutions for its patients. The new development massively increases the scope of the reach and accessibility by which the company’s therapy may be deployed. This facilitates more patients all over the world to get the relief they need while not having to leave the comfort of their homes. This is line with the company’s vision of improving patient outcomes with its nerve stimulation therapy platform, which initially focused on the treatment of various neurological conditions.

    Future Outlook for ECOR Stock

    Armed with the security of the patenting of its proprietary technology, ECOR stock is poised to capitalize on the opportunities and tenure afforded to it over the long term. The company is keen to spearhead market penetration in an effort to usher in significant and sustained increases in shareholder growth.

  • The Three Cheap Stocks to Keep in your Investment List

    The Three Cheap Stocks to Keep in your Investment List

    The global pandemic has affected many high price stocks and with much uncertainty, we have certain cheap stocks to watch for.

    Last year has been total devastation and things have turned upside down for most of the companies in the stock market. We have seen many companies whose dynamics have changed during the last years’ time. For instance, companies which totally relied upon retail store have understood the significance of online stores and are moving to e-market—now.

    In the meantime, the investor’s behavior changed due to rising uncertainty and for risk-averse investors, the cheap stocks with high potential are the best investment options. Let’s see the three cheap stocks for investment.

    Zomedica (ZOM)

    Zomedica (ZOM) is one of the most promising cheap stocks in the market. Zomedica is a development stage veterinary diagnostic and pharmaceutical company for dogs and cats. The company is well-positioned and has improved its performance during 2020 following a rise in pets’ products.

    Recently, Zomedica recorded the first veterinarian sale of TRUFORMA® and officially entered commercialization. This will help the company grow its sales and give a competitive edge in the market. It’s a long-term success story for the company and investors would be quite proud of it.

    Zomedica (ZOM) is trading on a lower side, which could be a perfect buy for investors. The future outlook seems solid. So, ZOM wouldn’t be a bad investment at all.

    Navient (NAVI)

    Navient (NAVI) provides loans to students. The company menacing time in 2020 as the borrowers disappear in quarantine. Reporting one of its worst ever, Navient saw 28.5% of its federal loan borrowers and 14.7% of its private loan borrowers hiding themselves during Q2. However, things improved with the following figures dropping to 13.8% and 3.9% on federal and private loans, respectively.

    Navient stock is trading around its new 52-week high price of $14 as the bullish sentiment continues to increase. The rising bulls are largely pushed by the anticipation of increasing recovery of the finance sector. Moreover, the company expects to see higher charge-offs during the year, jumping from 0.88% in 2020 to 3% in 2021. Overall, Navient is quite optimistic about its fortune this year, which will bring improvements in lending.

    Glu Mobile (GLUU)

    Glu Mobile (GLUU) has been performing radiantly, recently. The company was mostly driven by the announcement of EA following the all-cash buyout deal with Glu at an implied enterprise value of $2.1 billion.EA has high expectations from Glu’s rising sales and positive operating profits right away. The acquisition is expected to close in Q2 2021, based on the shareholder’s consent.

    In the fourth quarter, the company reported impressive outcomes with revenue jumping up to 25% year over year to $141.4 million. The GAAP net income rose to a record $23.9 million quarterly. While the free cash flow was also great with 46.2 million by the end of the quarter and $69.0 million by the year-end, up 132%. The prospects are strong for Glu Mobile (GLUU) as the acquisition is forthcoming.

  • 3 Top Marijuana Stocks to Invest for Long-term

    3 Top Marijuana Stocks to Invest for Long-term

    Will 2021 be a decider that should you go invest in marijuana stocks for the long-term? If so, pick these three.

    The marijuana industry is a diversified market where companies are engaged in research, distribution, medicine development, and recreational marijuana. Cannabis stocks really got the attention when the potential legalization of marijuana on a broader scale across the United States. The Biden administration is pretty much determined to go with legalizing the use of marijuana and support the industry to grow bigger, globally.

    Many marijuana companies have grown much bigger during one year’s time and there are continuously developing and expanding their ecosystem across the planet. So, let’s have a look at the three top marijuana stocks for investment in the long run.

    Green Thumb Industries (GTBIF)

    Green Thumb Industries (GTBIF) made strong progress during the past year due to growth in its home state of Illinois. The opening of the legal adult-use recreational marijuana market in the state is a great plus for the company in the coming years.

    The company has retail stores in 12 states across the country and operates 13 manufacturing facilities. Green Thumb also owns the license for over 96 retail cannabis stores and currently has opened less than half of them. With the growing market trend, we could see GTBIF open more and more retail stores in the future.

    In that premise, Green Thumb Industries is set to open its 9th store in Illinois and 55th in the country. While it will be opening its 56th retail store, Rise Meadville in Pennsylvania. The following two new openings are expected to take place on March 31, 2021. So, GTBIF sits on strong growth in the cannabis market for long-term investment.

    GW Pharmaceuticals (GWPH)

    GW Pharmaceuticals (GWPH) is a British pharmaceutical company famous for its multiple sclerosis treatment product nabiximols, the first natural cannabis plant derivate to gain market approval in the world.

    GW is one of the most decorated and well-established companies in the cannabis segment. It has a market cap of over $6.67 billion and is continuing to grow as the market expands. Recently, the company announced that its Type II variation application for EPIDYOLEX® received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). EPIDYOLEX is being prepared to be used for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC). It will be used to treat patients of two years of age and above. This is a big step forward to move towards the end result of the product.

    So, GW is changing things in the market, and is the key factor is that it belongs to medicine, which is always a strong point for a company.

    Scotts Miracle-Gro (SMG)

    Scotts Miracle-Gro (SMG) has driven with the following of the cannabis market trend. Scotts’ Hawthorne Gardening subsidiary is among the leading supplier of hydroponic gardening products to the cannabis industry.

    So, Hawthorne plays a vital role in the growth of Scotts Miracle-Gro. However, the company still makes a big chunk of money-half of its total revenue—from the sales of its garden products and consumer lawn. The positive is that Scotts’ main business has also succeeded during the pandemic. So, SMG can be a good bet for the long-term.

  • The 3 Top Transportation Stocks to Watch For in 2021

    The 3 Top Transportation Stocks to Watch For in 2021

    The transportation seems much better this year and things are recovering gradually.

    The transportation industry has mostly suffered during the course of the global pandemic. However, things eased off a bit by the late last year. Surprisingly, some companies from the transportation sector have seen massive growth since the pandemic hit. For instance, logistics companies have made huge bucks due to the rise in online orders.

    So, transportation stocks hold a strong potential to pump with things getting normal in the coming time. Let’s have a look at the three top transportation stocks to watch for this year.

    FedEx (FDX)

    The logistics giant, FedEx (FDX) shares have recently been trading high. The analysts have mixed opinions on the multinational delivery services firm, but they are mostly bullish and rate the stock a buy of around $250. As we write this, FDX trades around $274.18. So, investors must keep an eye on the stock and go for buy on low.

    FedEx reported Fiscal year third-quarter results that topped consensus estimates and reinstated guidance for the first time since the onset of the pandemic. Moreover, the balance sheet is also strong.

    As of Dec. 2020, 63 hedge funds’ portfolios were holding the stock. While FDX’s all-time high is 71. The investors have seen a decline in hedge fund interest in the stock of FedEx. But in the middle of everything, there lies an opportunity to make profits. So, keep watching FDX.

    Union Pacific (UNP)

    Union Pacific (UNP) is a railroad stock that is quite attractive for dividend-based investors. UNP has an extensive network of tracks in the western two-thirds of the U.S. The company ships everything including coal, chemicals, crops, and cars, among others.

    Union Pacific has good earnings prospects. The company is working on its expansion project which is set to open new ways in the future. TV host Jim Cramer has highlighted high-quality cyclical to buy on weakness. He mentioned UNP is among them and called the transporter “a one-stop-shop for the great reopening.” He added:

    “If you knew the score, you could confidently buy [Union Pacific] into weakness because this market loves the reopening plays. I bet it’s got a lot more room to run.”

    Kirby Corp. (KEX)

    Kirby Corporation (KEX) is the largest tank barge operator in the United States, transporting bulk liquid products across the country and certain other regions including the West, East, and Gulf Coasts along with Alaska and Hawaii to deliver bulk liquids to customers.

    Kirby’s Marines have been under the red zone and saw weak utilization during the fourth quarter of 2020. This is expected to improve gradually in the first quarter or maybe the second quarter and emerge as a strong business segment for the company later this year.

    Things are anticipated to get better in the next two years or so and Kirby will be set on the path to pre-pandemic levels. Especially, the increase in chemical production capacity during the pandemic will help the company recover swiftly. So, Kirby (KEX) is one stock to keep under your radar.

  • Top 3 Work-From-Home Stocks in 2021

    Top 3 Work-From-Home Stocks in 2021

    A little over a year ago, people were not even familiar with the term ‘work from home’ and now, because of this worldwide pandemic, almost everyone has worked from home one way or the other. The COVID-19 pandemic proved to be catastrophic for many companies but it also opened up many opportunities for companies as well as investors. With the introduction of work from home, this pandemic has changed the business model of many companies. Many big corporations such as Google and Facebook have even adopted this work from home for long term. This shift towards working online has created demand for digital platforms that are designed to help meet the requirements of working from home. A survey conducted by research and advisory firm Gartner showed that almost 80% company leaders are planning on allowing employees to work from home part time and 47% are planning to allow their employees to work from home full time. In another survey conducted by PwC of 669 CEOs, almost 78% agreed that work from home will be implemented in the long run. Since office based work is substituted by work from home, we’ll be looking at some of the best work from home stocks in 2021. Here are top 3 work from home stocks for 2021:

    Zoom Video Communications, Inc. (ZM)

    Zoom has witnessed an immense increase in its demand amidst this global pandemic. Zoom’s model has helped businesses all over the world because of its remote working model. The company currently carries Zacks rank #3 (Hold). In February 2020, Zoom’s stock was valued at $87.66 and as of yesterday it closed at an astonishing $337.43. This accounts to an increment of almost 285% in little over a year. Every day, almost 200 million people login to Zoom, compared to 10 million users just before the pandemic. In the US, Zoom is the most used conferencing application and has 43% market share. The fundamentals of this company looks promising, and investors should surely keep their eyes on this stock’s movements.

    DocuSign Inc. (DOCU)

    DocuSign is an organization that provides e-signature solutions and allows companies to manage agreements online. DocuSign has benefited many organizations that transferred to work from home amidst the global pandemic. Since many companies have shifted their business model online, this e-signature solution is to benefit them in long term. Organizations such as Oracle and Microsoft have integrated themselves with DocuSign which will further help them grow their customer base. The company carries a Zacks Rank #3 (hold). To date, the company’s shares have soared up to 143% in a year. In March 2020 the stock price was $84.02 and it has increased to $204.31 as of 5th March 2021. According to Zacks Consensus Estimate for fiscal year 2022, the earnings has estimated to be moved up by 28.2% to $1.09 per share over the same time frame.

    Dropbox (DBX)

    Dropbox, a cloud service provider, has become a crucial part of many organizations in this digital age. Dropbox has an estimate of over 600 million users. During the coronavirus pandemic, cloud storage and other online service providers saw a dramatic increase in their usage and demand as consumers shifted towards these platforms. Dropbox witnessed a rise of nearly 25% in daily trials of its premium package. Dropbox has been consistently profitable and for 8 consecutive quarters their earnings per share have risen. Dropbox stock has risen up by 30% to date, as compared to the price before the coronavirus pandemic.

  • Why shares of electroCore Inc. (ECOR) stock are popping high in Pre-Market?

    Why shares of electroCore Inc. (ECOR) stock are popping high in Pre-Market?

    Shares of electroCore Inc. (ECOR), a medical technology company, are popping high in pre-market on the 1st day of March 2021. As of 5:40 AM EST, the share price reached $3.51 recording a gain of 61.75%. Let’s deep dive to understand the reason behind this bull.

    What’s Happening?

    Company on February 28, 2021, announced that it has signed an agreement with Medistar2 PTY Limited. According to the agreement, Medistar will now serve as the exclusive distributor of thegammaCore Sapphire non-invasive vagus nerve stimulator (nVNS) in Australia. The core purpose is to cure primary headache disorders by supplying therapy to patients. The announcement was made after getting approval from the Australian Therapeutic Goods Administration (TGA) to promote and sell the gammaCore Sapphire family of products.

    The agreement is valid for the next three years and contains specific customary terms and conditions which also include minimum purchase requirements. Medistar will launch gammaCore Sapphire at the 2021 ANZHS Headache Annual Scientific Two-day Meeting oncoming March 13-14. 

    GammaCore Sapphire is a drug-free device, and it has no side effects. Furthermore, it will also help to explore interfacing with the vagus nerve and the anti-inflammatory pathway.

    Conclusion:

    Investors are taking interest in the ECOR stock after its agreement with Medistar2 PTY Limited. The company has a good future in the upcoming days as it looks like the ECOR will produce a massive profit by selling its headache relief device in Australia.

  • Early Morning Vibes: Don’t Miss On These 4 Growth Stocks

    Early Morning Vibes: Don’t Miss On These 4 Growth Stocks

    In the recent times, Aviation stocks have suffered a serious crash. Covid-19 shut down the entire business. But US aviation stocks, such as United Airlines and Delta Airlines, are on the rise again. European aviation stocks are also doing well. Air France-KLM ended 2020 with a loss of €7.1 billion, but the share is rising again. And one of the best airline stocks is Ryanair. The Irish airline’s share is already above pre-corona levels. The optimism of investors must be sought in the rollout of the vaccinations and also the introduction of a kind of vaccine passport, which apparently more and more politicians are in favor.If vaccinations gain speed and everyone who wants to go on holiday by plane must be able to present proof of vaccination, more people will be triggered to actually get vaccinated.

    For Bank of America, an oil price of $100 is realistic within this and a few years. The drivers would be better fundamentals and monetary policy. Futures prices in the future are priced considerably more dearly and open interest has also risen sharply for options with a strike $100. Open interest has increased from 500 to 3,950 option contracts in one week.The rising open interest indicates an increasing number of open option contracts, a significant increase and interest from market participants. In the meantime, there are voices that OPEC + must increase production to meet (future) demand.

    It looks like Warren Buffett has been busy last year. On the one hand, Berkshire Hathaway has more than double the volume (purchases and sales) compared to 2019. This will likely have been mainly due to sector rotation, as Warren Buffett is known for its long-term investing. Unless he has suddenly become a day trader. But let’s not assume this. Berkshire Hathaway further repurchased $24.7 billion of its own shares.In the newsletter sent out by Berkshire Hathaway this weekend, it is also noticeable that the amount of cash has increased quarter after quarter in recent years. In Q4 2020, Berkshire Hathaway was on a cash mountain of $138.3 billion. In 2020, the share of financial institutions in the holding decreased their portfolio from 41% to 24%. Warren Buffett and his partner Charly Munger appear to be seeing something in the energy and telecommunications sector. A large interest was taken in Chevron and Verizon Communications.

    Today Top Movers

    NIO Limited (NIO) stock soared 5.9% to $48.48 in the pre-market trading.

    SOS Limited (NYSE: SOS) shares are trading up 28.3% at $6.12 at the time of writing.

    electroCore Inc. (ECOR) grew over 58.06% at $3.43 in pre-market trading today after declaring an exclusive distribution agreement with Medistar following regulatory approval in Australia.

    Socket Mobile Inc. (SCKT), a Computer Hardware company, rose about 42.72% at $15.0 in pre-market trading Monday. The firm today reported it has licensed SpringCard SAS core contactless technology.

    Top Upgrades & Downgrades

    JP Morgan turned bullish on Plug Power Inc. (PLUG), upgrading the stock to “Overweight” and assigning a $65.0 price target, representing a potential upside of 34.35% from Friday’s close. 

    CME Group Inc. (CME) has won the favor of Keefe Bruyette’s equity research team. The firm upgraded the shares from Underperform to Market Perform and moved their price target to $197. 

    Spirit AeroSystems Holdings Inc. (SPR) received an upgrade from analysts at Morgan Stanley, who also set their one-year price target on the stock to $50. They changed their rating on SPR to Overweight from Equal Weight in a recently issued research note. 

    Earlier Monday JP Morgan reduced its rating on Agios Pharmaceuticals Inc. (AGIO) stock to Neutral from Overweight and assigned the price target to $54. 

    Morgan Stanley analysts reduced their investment ratings, saying in research reports covered by the media that it’s rating for TechnipFMC plc (FTI) has been changed to Equal-Weight from Overweight and the new price target is set at $8.8. 

    Analysts at RBC Capital downgraded Pactiv Evergreen Inc. (PTVE)’s stock to Sector Perform from Outperform Monday.

    Latest Insider Activity

    ContextLogic Inc. (WISH) Chief Accounting Officer Just Brett announced the sale of shares taking place on Feb 24 at $19.65 for some 36,901 shares. The total came to more than $0.73 million. 

    Walmart Inc. (WMT) Director WALTON S ROBSON sold on Feb 26 a total of 356,175,368 shares at $130.64 on average. The insider’s sale generated proceeds of almost $92.81 million. 

    Macy’s Inc. (M) Director VARGA PAUL C declared the purchase of shares taking place on Feb 26 at $15.25 for some 13,115 shares. The transaction amount was around $0.2 million. 

    Coeur Mining Inc. (CDE) Chairman (non-executive) MELLOR ROBERT E bought on Feb 24 a total 185,233 shares at $10.53 on average. The purchase cost the insider an estimated $10,530.

    Important Earnings

    Top US earnings releases scheduled for today include Workhorse Group Inc. (NASDAQ: WKHS). It will announce its Dec 2020 financial results. The company is expected to report earnings of -$0.13 per share from revenues of $1.32M in the three-month period. 

    Analysts expect Perrigo Company plc (PRGO) to report a net income (adjusted) of $1.00 per share when the company releases its quarterly results shortly. Revenue for the fiscal quarter ended Dec 2020 is predicted to come in at $1.32B. 

    Inovio Pharmaceuticals, Inc. (INO), due to announce earnings after the market closes today, is expected to report earnings of -$0.22 per share from revenues of $1.11M recently concluded in a three-month period.

  • Three Top Consumer Stocks for long-term Investment

    Three Top Consumer Stocks for long-term Investment

    Let’s see the best possible investment options in the consumer market during the pandemic crisis.

    The consumer market has been a bit shaky in most of the sectors due to uneconomical circumstances amid the COVID-19 pandemic. Still, many of the consumer stocks have performed remarkably well.

    Among the consumer stocks, there are two most prominent segments including consumer discretionary business and consumer staples. Both of these consumer segments have their pros and cons.

    As we move ahead into 2021, investors would be keen on what stocks they’re putting in their shopping carts. Consumer stocks are usually slow growth stocks and investors with the Buffet mindset are the perfect match for the long-term investment—in consumer stocks. So, let’s have a look at the three top consumer stocks for investment in the long-term.

    Qurate Retail (QRTEA)

    Qurate Retail (QRTEA) is an e-commerce service provider. The company partners with TV networks and e-commerce sites, mobile applications, social media, and similar outlets to provide video and digital commerce services worldwide.

    In the last quarterly reports, the company came up with strong and promising results. Qurate generated net retail revenue of $3.4 billion, jumping by 10% year-over-year. While the online sales grew 15% to $2.1 billion, which were almost 62% of the total revenue. The diluted earnings were $0.80per share.

    Moreover, the company delivered special dividends to its shareholders. The cash dividend of $1.50 per share was distributed on Sep. 14, 2020. Qurate also issued the newly preferred stock dividend of $3.00 per share. Following that, the company’s QVC has issued$500 million of 4.375% senior notes due 2028, and the proceeds will be used to tender for outstanding $500 million 5.125% senior notes due 2022.

    Looking into the long-term, Qurate Retail (QRTEA) can be a solid bet. The company will be taking part in the Morgan Stanley Technology, Media, and Telecom Conference on Monday, March 1st. So, keep an eye on that event, there might be some exciting news coming.

    Altria Group (MO)

    One of the largest producers and markers of tobacco, Altria Group (MO) is one of the promising long-term bets in the consumer segment. For this year, the company has plans of investment to expand the availability and awareness of Altria’s non-combustible products.

    Based on different investments in 2021, the company has updated the outlook for this year. The company has reaffirmed its full-year guidance and expects the adjusted diluted earnings to be between $4.49 to $4.62 per share, which means a growth of 3% to 6% compared to that in 2020. Altria Group (MO) is working on some key projects and anticipates 2021 to be a good year. So, MO is one of the potential investment options from the consumer segment.

    General Mills (GIS)

    General Mills (GIS) is well-positioned to move forward and has some solid plans to make things look good for the company.

    During the first fiscal quarter of 2021, the demand for at-home food was on a rise. The company expects the demand to increase in the current and upcoming quarters, as the situations unfold. The CFO of General Mills, Kofi Bruce on Yahoo Finance Live told they are expecting high demand for the next quarter. He stated:

    “We are continuing to make investments in capabilities that will help us when we come out on the other side of COVID. So higher operating costs, but offset by higher leverage as we’re getting a lot more operating leverage out of our assets. We certainly feel confident that demand will remain elevated for at least the next quarter.”

    General Mills (GIS) has been one of the top-performing stocks in 2020 and seems to continue the bullish run this year.